Inozyme Pharma Inc expected to post a loss of 41 cents a share - Earnings Preview

Inozyme Pharma

02/05/2025 14:14

Inozyme Pharma Inc INZY.OQ INZY.O is expected to show no change in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Inozyme Pharma Inc is for a loss of 41 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Inozyme Pharma Inc is $13.50​, above​ its last closing price of $1.21. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.41
-0.41
-0.41
Met
-1
Sep. 30 2024
-0.44
-0.44
-0.39
Beat
10.5
Jun. 30 2024
-0.39
-0.39
-0.44
Missed
-13​
Mar. 31 2024
-0.36
-0.36
-0.38
Missed
-5.6
​​Dec. 31 2023
-0.34
-0.32
-0.33
Missed
-3.6
Sep. 30 2023
-0.31
-0.32
-0.29
Beat
8.3​
Jun. 30 2023
-0.40
-0.43
-0.35
Beat
19.2
Mar. 31 2023
-0.44
-0.45
-0.40
Beat
10.3

This summary was machine generated May 2 at 13:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)